FDA Inspection 1071681 — Raybow (Suzhou) Pharmaceutical Co., Ltd.
The FDA completed an inspection of Raybow (Suzhou) Pharmaceutical Co., Ltd. on October 18, 2018 in Suzhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- October 18, 2018
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Suzhou (China)